News
CPhI Annual Report 2020 Part 1: 2025 will see cell and gene therapy capacity shortages in the USA and 10+ mAb approvals in China
CPhI Annual Report – launched ahead of the first CPhI Festival of Pharma (5-16 October, 2020), the world’s largest digital pharma Expo – predicts dramatic growth of new mAb production in China, capacity shortages for cell and gene therapies...
News
Gilead Sciences to acquire ADC developer Immunomedics for $21bn
Gilead Sciences, Inc. and Immunomedics announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously...
News
Oxford University resume Covid-19 vaccine trial
Oxford University on Saturday, 13th Sep. 2020 announced resuming coronavirus vaccine trials, the study which was suspended following a reported side-effect in a UK patient. Oxford University, developing this vaccine with pharmaceutical company AstraZeneca confirmed the restart across all...
News
DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India
India's top drug regulator-- Drugs Controller General of India (DCGI) has granted permission to Serum Institute of India (SII) to conduct phase 2 and 3 human clinical trials in India on the potential covid-19 vaccine, a senior government official...
News
Serum Institute of India COVID-19 Vaccine advances to trial for phase-III on 1500 Indian patients
Serum institute has completed phase II-B3 trails and will commence phase-III trail after clearances. The third phase trail will be tested on 1500 patients at 14 locations. Balram Bhargava, Director general of the Indian Council of Medical Research, said,...
News
Paradigm4 launches Revels Single Cell app for analysing large-scale data sets
Paradigm4, specialist in scientific data management and scalable computation, has launched its REVEAL: Single CellTM app to offer biopharmaceutical developers the ability to break through the data wrangling and programming challenges associated with the analysis of large-scale, single-cell datasets.
The...
News
Lubrizol Life Science Health awarded grant for generic contraceptive injection research to advance women’s health worldwide
The Lubrizol Corporation has announced that the contract development and manufacturing organization (CDMO) of Lubrizol Life Science Health (LLS Health) has been awarded a grant to support its research on injectable contraceptive formulations designed to bring accessible contraceptive products...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
